Inhibrx, Inc. Ex-distribution When-Issued
INBXV
NASDAQ Global Market30.85
USD
- -
- -
Return %
Stock
S&P500
1Y
- -
26.53
3Y
-1.28
76.60
5Y
-1.28
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Mark Paul Lappe
- Full Time Employees
- 166
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Similar Companies
- Business
- Inhibrx, Inc. Ex-Distribution When-Issued (INBXV) represents the residual trading symbol for shares of the former Inhibrx, Inc. following its May 2024 corporate restructuring, which included a pro rata spin-off of 92% of Inhibrx Biosciences, Inc. common stock to shareholders at a ratio of one share for every four held as of the May 17, 2024 record date, and the concurrent sale of its INBRX-101 alpha-1 antitrypsin deficiency asset to Sanofi S.A. for up to $2.2 billion in value. Prior to these transactions, Inhibrx, Inc., founded in 2010 and headquartered in La Jolla, California, operated as a clinical-stage biopharmaceutical company developing novel biologic therapeutic candidates using proprietary modular protein engineering platforms, including multivalent formats for optimized agonist function; its pipeline targeted oncology, orphan diseases, and infectious diseases with key programs such as INBRX-101, a recombinant AAT augmentation therapy in Phase 2 trials for AATD, alongside INBRX-109 (ozekibart), a tetravalent death receptor 5 agonist for chondrosarcoma, Ewing sarcoma, and solid tumors; INBRX-106, a hexavalent OX40 agonist for non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, and gastric cancer; and earlier assets like INBRX-105. The spin-off created Inhibrx Biosciences, Inc. (Nasdaq: INBX), which retained the non-INBRX-101 assets including INBRX-109 and INBRX-106, corporate infrastructure, and ongoing clinical trials now reporting positive topline Phase 2 results for ozekibart in chondrosarcoma with a planned Q2 2026 Biologics License Application filing, expansion cohorts in colorectal cancer and Ewing sarcoma, and key 2025 data readouts; subsequent developments for Inhibrx Biosciences encompass a January 2025 $100 million initial term loan (expandable to $150 million) from Oxford Finance LLC, leadership transitions with the appointment of Carlos Bais as Chief Scientific Officer and David Matly as President, and Q3 2025 cash position of $153.1 million supporting pipeline advancement primarily in the United States.